{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:33:37Z","timestamp":1695515617283},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.beha.2010.01.003","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T09:10:54Z","timestamp":1277370654000},"page":"155-166","source":"Crossref","is-referenced-by-count":16,"title":["Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Rong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2010.01.003_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2010.01.003_bib2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ctrv.2007.08.003","article-title":"Recent progress in the management of chronic lymphocytic leukemia","volume":"33","author":"Robak","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2010.01.003_bib3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2010.01.003_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1046\/j.1365-2141.1996.d01-1856.x","article-title":"In leukaemic CD5+B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis","volume":"94","author":"Gottardi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2010.01.003_bib7","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib8","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Pepper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2405052","article-title":"Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia","volume":"22","author":"Veronese","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2010.01.003_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib12","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib13","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1182\/blood-2004-07-2713","article-title":"A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival","volume":"105","author":"Alvi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib14","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","article-title":"Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V89.2.630","article-title":"Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions","volume":"89","author":"Zhou","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccr.2007.07.011","article-title":"Life, death, BH3 profiles, and the salmon mousse","volume":"12","author":"Green","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2010.01.003_bib17","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/1078-0432.CCR-07-1598","article-title":"BCL-2 family proteins: critical checkpoints of apoptotic cell death","volume":"13","author":"Danial","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2010.01.003_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2010.01.003_bib21","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib22","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule Obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2010.01.003_bib23","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-06-1574","article-title":"Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1","volume":"13","author":"Mohammad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib24","first-page":"855","article-title":"Oblimersen for the treatment of patients with chronic lymphocytic leukemia","volume":"3","author":"Cheson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.beha.2010.01.003_bib25","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-07-5723","article-title":"The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells","volume":"68","author":"Soundararajan","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrm830","article-title":"IAP proteins: blocking the road to death's door","volume":"3","author":"Salvesen","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1535-6108(03)00340-4","article-title":"Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers?","volume":"5","author":"Huang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2010.01.003_bib28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2005-02-0695","article-title":"Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis","volume":"106","author":"Kater","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib29","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1128\/MCB.16.7.3291","article-title":"TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes","volume":"16","author":"Yankulov","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","article-title":"Controlling the elongation phase of transcription with P-TEFb","volume":"23","author":"Peterlin","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.beha.2010.01.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/med.20172","article-title":"Pharmacological targeting of CDK9 in cardiac hypertrophy","author":"Krystof","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.beha.2010.01.003_bib32","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1093\/nar\/5.9.3325","article-title":"Inhibition of mammalian RNA polymerase by 5,6-dichlororibofuranosylbenzimidazole (DRB) and DRB triphosphate","volume":"5","author":"Dreyer","year":"1978","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.beha.2010.01.003_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1101\/sqb.1998.63.365","article-title":"RNA polymerase II elongation control","volume":"63","author":"Peng","year":"1998","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib34","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1040-8428(00)00124-4","article-title":"Mechanisms of action of flavopiridol","volume":"38","author":"Sedlacek","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.beha.2010.01.003_bib36","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1517\/13543784.9.12.2903","article-title":"Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status","volume":"9","author":"Kelland","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.beha.2010.01.003_bib37","first-page":"3527","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1","volume":"8","author":"Gojo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.873.3.7","article-title":"Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?","volume":"3","author":"Grant","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2010.01.003_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib40","doi-asserted-by":"crossref","first-page":"373s","DOI":"10.1200\/jco.2008.26.15_suppl.7007","article-title":"Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine","volume":"243","author":"De Azevedo","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.beha.2010.01.003_bib42","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1128\/JVI.75.16.7266-7279.2001","article-title":"Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors","volume":"75","author":"Wang","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.beha.2010.01.003_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.beha.2010.01.003_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2010.01.003_bib45","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-04-2264","article-title":"In vitro and in vivo pharmacokinetic\u2013pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202","volume":"11","author":"Raynaud","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nm1047","article-title":"Bioluminescent imaging of Cdk2 inhibition in vivo","volume":"10","author":"Zhang","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2010.01.003_bib47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdi217","article-title":"In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas","volume":"16","author":"Lacrima","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib48","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/jm0305568","article-title":"N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent","volume":"47","author":"Misra","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.beha.2010.01.003_bib49","article-title":"Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor","volume":"22","author":"McCormick","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib50","article-title":"A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors","volume":"22","author":"Shapiro","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib51","article-title":"A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors","volume":"22","author":"Jones","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib52","first-page":"491","article-title":"SNS-032 is a potent and selective inhibitor of Cdk2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins","volume":"47","author":"Nuwayhid","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","article-title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","volume":"26","author":"Heath","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.beha.2010.01.003_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I study of SNS-032, a potent and specific Cdk2, 7 and 9 inhibitor, in patients with advanced Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM)","author":"Tong","year":"2010","journal-title":"Journal of clinical Oncology"},{"key":"10.1016\/j.beha.2010.01.003_bib55","unstructured":"Hawtin RE, Cohen R, Haas N et\u00a0al. SNS-032 exhibits dose-dependent mechanism-based inhibition of cdk7 and cdk9 in peripheral blood mononuclear cells from patients with advanced cancers treated in an ongoing phase 1 trial. 12th Congress of the European Hematology Association. Vienna, Austria; 2007."},{"key":"10.1016\/j.beha.2010.01.003_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3747\/co.v16i2.428","article-title":"Development of cell-cycle inhibitors for cancer therapy","volume":"16","author":"Dickson","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib57","unstructured":"Johnson AJ, Smith AL, Raymond CA et\u00a0al. The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. Denver, CO.: Philadelphia (PA); 2009."},{"key":"10.1016\/j.beha.2010.01.003_bib58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1535-7163.MCT-08-0890","article-title":"Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines","volume":"8","author":"Squires","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2010.01.003_bib59","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1021\/jm0606138","article-title":"Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-diflu oro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity","volume":"49","author":"Chu","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.beha.2010.01.003_bib60","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-06-0355","article-title":"In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials","volume":"5","author":"DePinto","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2010.01.003_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.3528","article-title":"A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)","volume":"25","author":"Diab","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2010.01.003_bib62","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","article-title":"In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2010.01.003_bib63","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/leu.2008.378","article-title":"Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma","volume":"23","author":"Raje","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2010.01.003_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biopha.2006.06.003","article-title":"Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709","volume":"60","author":"Siemeister","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.beha.2010.01.003_bib65","article-title":"A novel multi-targeted small molecular inhibitor RGB 286638 triggers apoptosis and necrosis in multiple myeloma via dual cell death pathways","author":"Diana","year":"2009","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00280-009-0968-y","article-title":"A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours","volume":"64","author":"Scott","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.beha.2010.01.003_bib67","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","article-title":"Homoharringtonine: history, current research, and future direction","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2010.01.003_bib68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","article-title":"U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome","volume":"389","author":"Gurel","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib69","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib70","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","article-title":"A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3239.3239","article-title":"Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation \u2013 results of An Ongoing Multicenter Phase II Study","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib72","article-title":"Homoharringtonine downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia cells","volume":"50","author":"Guo","year":"2009","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib73","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2010.01.003_bib74","doi-asserted-by":"crossref","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","article-title":"Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol","volume":"4","author":"Cencic","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2010.01.003_bib75","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","article-title":"The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo","volume":"113","author":"Lucas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2010.01.003_bib77","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.003_bib78","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2010.01.003_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib80","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib81","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.003_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-10-research0041","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol","volume":"2","author":"Lam","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0968-0004(00)89102-1","article-title":"AU-rich elements: characterization and importance in mRNA degradation","volume":"20","author":"Chen","year":"1995","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.beha.2010.01.003_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/35067025","article-title":"The cap-to-tail guide to mRNA turnover","volume":"2","author":"Wilusz","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2007.11.024","article-title":"Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1","volume":"29","author":"Vlasova","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.beha.2010.01.003_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(96)10031-1","article-title":"PEST sequences and regulation by proteolysis","volume":"21","author":"Rechsteiner","year":"1996","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.beha.2010.01.003_bib87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2013the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beha.2010.01.003_bib88","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib89","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins","volume":"51","author":"Park","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.beha.2010.01.003_bib90","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","article-title":"Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275","volume":"201","author":"Losiewicz","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.beha.2010.01.003_bib91","doi-asserted-by":"crossref","first-page":"28345","DOI":"10.1074\/jbc.C000446200","article-title":"Flavopiridol inhibits P-TEFb and blocks HIV-1 replication","volume":"275","author":"Chao","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2010.01.003_bib92","first-page":"4634","article-title":"Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol","volume":"59","author":"Carlson","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2010.01.003_bib93","doi-asserted-by":"crossref","first-page":"30339","DOI":"10.1074\/jbc.M303969200","article-title":"Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation","volume":"278","author":"Solomon","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2010.01.003_bib94","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1073\/pnas.81.22.7046","article-title":"Extreme Instability of myc mRNA in normal and transformed human cells","volume":"81","author":"Dani","year":"1984","journal-title":"PNAS"},{"key":"10.1016\/j.beha.2010.01.003_bib95","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/j.1460-2075.1985.tb03885.x","article-title":"Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle","volume":"4","author":"Rabbitts","year":"1985","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.beha.2010.01.003_bib96","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1083\/jcb.128.6.1173","article-title":"The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2","volume":"128","author":"Yang","year":"1995","journal-title":"J Cell Biol"},{"key":"10.1016\/j.beha.2010.01.003_bib97","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/sj.leu.2403491","article-title":"Potent antileukemic interactions between flavopiridol and TRAIL\/Apo2L involve flavopiridol-mediated XIAP downregulation","volume":"18","author":"Rosato","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2010.01.003_bib98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yexcr.2004.08.029","article-title":"Survivin interacts with Smac\/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis","volume":"302","author":"McNeish","year":"2005","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.beha.2010.01.003_bib99","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.3495884","article-title":"Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation","volume":"236","author":"Reed","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.beha.2010.01.003_bib100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0145-2126(95)00103-4","article-title":"bcl-2 Protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells","volume":"20","author":"Blagosklonny","year":"1996","journal-title":"Leuk Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692610000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692610000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T18:49:26Z","timestamp":1685645366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692610000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1521692610000046"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2010.01.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}